Search Results 41-50 of 13644 for Relaxin-2
... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...
... 2 dose (RP2D) for future study after treatment with SONALA-001 in combination ... Go to page 22 · Go to page 33 · Go to page 44 · Go to page 55 · NextNext Page.
... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...
... 2 mL oral solution",122.46 636000003,59365512801,copper 380 square mm ... 2(PF) 10 mcg/0.5 mL (final) IM solution,178.27 636000003,58160095901 ...
Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...
Cohort 2 includes (1) muCALR+ primary MF, and (2) muCALR+ secondary MF. ... Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.